Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Michelson

Showing results (181-190 of 252) with videos related to

Pageof 26
Sort By:
Journal of the American College of Cardiology|January 1, 1995
Guidelines for training in adult cardiovascular medicine. Core Cardiology Training Symposium (COCATS). Task Force 1: training in clinical cardiologyJ S Alpert, W J Arnold, B R Chaitman, et al.
Pacing and Clinical Electrophysiology : PACE|March 1, 1986
Effects of AV sequential versus asynchronous AV pacing on pulmonary hemodynamicsL S Dreifus, H Mitamura, A Rhauda, et al.
Journal of Medicinal Chemistry|September 1, 1970
Synthesis and activity of some 3-aryl- and 3-aralkyl-1,2,3,4-tetrahydro-4-oxo-6-quinazolinesulfonamidesB V Shetty, L A Campanella, T L Thomas, et al.
Archives of Internal Medicine|August 13, 2008
The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programHertzel C Gerstein, Karl Swedberg, Jonas Carlsson, et al.
American Journal of Hypertension|November 1, 1989
A multicenter double-blind study of the efficacy and safety of once and twice daily dilevalol compared to propranololJ A Schoenberger, J D Wallin, J I Gorwit, et al.
The American Journal of Cardiology|March 12, 1999
Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study InvestigatorsT P Bell, V DeQuattro, K C Lasseter, et al.
Clinical Therapeutics|July 15, 1998
Long-term efficacy, tolerability, and safety of the combination of enalapril and felodipine ER in the treatment of hypertension. Enalapril-Felodipine ER Factorial Study GroupA H Gradman, N R Cutler, P J Davis, et al.
Circulation|February 1, 1988
Inducible sustained ventricular tachycardia 4 years after experimental canine myocardial infarction: electrophysiologic and anatomic comparisons with early healed infarctsR F Hanich, C D de Langen, A H Kadish, et al.
The American Journal of Cardiology|May 1, 1978
Fascicular conduction distrubances after coronary bypass surgeryS M Zeldis, J Morganroth, L N Horowitz, et al.
The American Journal of Cardiology|October 30, 1998
Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study InvestigatorsM Reif, W B White, T C Fagan, et al.
Pageof 26

Showing results (181-190 of 252) with videos related to

Sort By:
Pageof 26
Journal of the American College of Cardiology|January 1, 1995
Guidelines for training in adult cardiovascular medicine. Core Cardiology Training Symposium (COCATS). Task Force 1: training in clinical cardiologyJ S Alpert, W J Arnold, B R Chaitman, et al.
Pacing and Clinical Electrophysiology : PACE|March 1, 1986
Effects of AV sequential versus asynchronous AV pacing on pulmonary hemodynamicsL S Dreifus, H Mitamura, A Rhauda, et al.
Journal of Medicinal Chemistry|September 1, 1970
Synthesis and activity of some 3-aryl- and 3-aralkyl-1,2,3,4-tetrahydro-4-oxo-6-quinazolinesulfonamidesB V Shetty, L A Campanella, T L Thomas, et al.
Archives of Internal Medicine|August 13, 2008
The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programHertzel C Gerstein, Karl Swedberg, Jonas Carlsson, et al.
American Journal of Hypertension|November 1, 1989
A multicenter double-blind study of the efficacy and safety of once and twice daily dilevalol compared to propranololJ A Schoenberger, J D Wallin, J I Gorwit, et al.
The American Journal of Cardiology|March 12, 1999
Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study InvestigatorsT P Bell, V DeQuattro, K C Lasseter, et al.
Clinical Therapeutics|July 15, 1998
Long-term efficacy, tolerability, and safety of the combination of enalapril and felodipine ER in the treatment of hypertension. Enalapril-Felodipine ER Factorial Study GroupA H Gradman, N R Cutler, P J Davis, et al.
Circulation|February 1, 1988
Inducible sustained ventricular tachycardia 4 years after experimental canine myocardial infarction: electrophysiologic and anatomic comparisons with early healed infarctsR F Hanich, C D de Langen, A H Kadish, et al.
The American Journal of Cardiology|May 1, 1978
Fascicular conduction distrubances after coronary bypass surgeryS M Zeldis, J Morganroth, L N Horowitz, et al.
The American Journal of Cardiology|October 30, 1998
Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study InvestigatorsM Reif, W B White, T C Fagan, et al.
Pageof 26